H.C. Wainwright reiterates a Buy rating on NVAX with a price target of $207 | NVAX Message Board Posts


NVAX   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  173261 of 184140  at  3/23/2022 11:26:51 AM  by

craigm


H.C. Wainwright reiterates a Buy rating on NVAX with a price target of $207

 

Analysts Are Bullish on These Healthcare Stocks: Novavax (NVAX), Indaptus Therapeutics (INDP)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Novavax (NVAXResearch Report), Indaptus Therapeutics (INDPResearch Report) and scPharmaceuticals (SCPHResearch Report) with bullish sentiments.

Novavax (NVAX)

In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Novavax, with a price target of $207.00. The company’s shares closed last Tuesday at $83.80, close to its 52-week low of $65.82.

According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 27.9% and a 37.2% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Aridis Pharmaceuticals, Eledon Pharmaceuticals, and Citius Pharmaceuticals.

Currently, the analyst consensus on Novavax is a Moderate Buy with an average price target of $179.86, representing a 130.4% upside. In a report issued on March 14, Jefferies also assigned a Buy rating to the stock with a $198.00 price target.

https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-novavax-nvax-indaptus-therapeutics-indp


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 18  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
173283 Re: H.C. Wainwright reiterates a Buy rating on NVAX with a price target of $207 BillyT 2 3/23/2022 3:14:31 PM


Financial Market Data provided by
.
Loading...